Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
VERTEX PHARMACEUTICALS INC / MA (VRTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/01/2023 8-K Quarterly results
Docs: "Vertex Reports First Quarter 2023 Financial Results"
08/04/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
10/25/2016 8-K Form 8-K - Current report
07/27/2016 8-K Form 8-K - Current report
04/27/2016 8-K Quarterly results
Docs: "Amendment to Amended and Restated By-laws",
"Vertex Reports First Quarter 2016 Financial Results -First quarter 2016 cystic fibrosis product revenues of $394 million; $223 million for ORKAMBI ® and $171 million for KALYDECO ® - -Provides 2016 guidance for ORKAMBI product revenues of $1.0 to $1.1 billion; increases 2016 guidance for KALYDECO product revenues to $685 to $705 million- -Provides update on approved CF medicines and pipeline of investigational medicines-"
10/28/2015 8-K Quarterly results
Docs: "Vertex Reports Third Quarter 2015 Financial Results -Third quarter 2015 revenues of $310 million, including net product revenues of $131 million for ORKAMBI ® and $166 million for KALYDECO ® in cystic fibrosis- -Vertex increases guidance for 2015 KALYDECO net revenues; now expects KALYDECO revenues of $605 to $620 million-"
07/29/2015 8-K Quarterly results
Docs: "Vertex Reports Second Quarter 2015 Financial Results -Second quarter 2015 total revenues of $166 million, including net product revenues of approximately $155 million for KALYDECO ® in cystic fibrosis- -Vertex increases guidance for total 2015 KALYDECO net revenues; now expects KALYDECO revenues of $575 to $590 million- -ORKAMBI TM launch underway following FDA approval on July 2-"
04/29/2015 8-K Quarterly results
Docs: "Vertex Reports First Quarter 2015 Financial Results -First quarter 2015 total revenues of $139 million, including net product revenues of $130 million for KALYDECO ® in cystic fibrosis- -Cash, cash equivalents and marketable securities of approximately $1.2 billion on March 31, 2015-"
10/28/2014 8-K Quarterly results
Docs: "Vertex Reports Third Quarter 2014 Financial Results"
07/29/2014 8-K Quarterly results
Docs: "Vertex Reports Second Quarter 2014 Financial Results and Provides Updates on Key Research and Development Programs"
05/01/2014 8-K Quarterly results
Docs: "Vertex Reports First Quarter 2014 Financial Results and Provides Updates on Key Business Priorities -Net product revenues of $100 million for KALYDECO in cystic fibrosis- -Cash, cash equivalents and marketable securities of $1.32 billion on March 31, 2014- -Six-month dosing period complete for Phase 3 TRAFFIC and TRANSPORT studies of lumacaftor in combination with ivacaftor for people with CF homozygous for the F508del mutation-"
10/29/2013 8-K Form 8-K - Current report
07/29/2013 8-K Form 8-K - Current report
04/30/2013 8-K Quarterly results
Docs: "EXHIBIT"
11/01/2012 8-K Form 8-K - Current report
07/30/2012 8-K Form 8-K - Current report
04/26/2012 8-K Form 8-K - Current report
07/28/2011 8-K Form 8-K - Current report
05/03/2011 8-K Quarterly results
Docs: "Vertex Reports First Quarter 2011 Financial Results and Reviews Milestones for Key Development Programs"
10/25/2010 8-K Form 8-K - Current report
07/28/2010 8-K Form 8-K - Current report
04/21/2010 8-K Form 8-K - Current report
10/26/2009 8-K Form 8-K - Current report
08/05/2009 8-K Form 8-K - Current report
04/16/2009 8-K Form 8-K - Current report
10/27/2008 8-K Form 8-K - Current report
07/31/2008 8-K Form 8-K - Current report
04/21/2008 8-K Form 8-K - Current report
10/29/2007 8-K Form 8-K - Current report
07/24/2007 8-K Form 8-K - Current report
04/30/2007 8-K Form 8-K - Current report
10/26/2006 8-K Form 8-K - Current report
07/26/2006 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy